Sherbrooke Park Advisers LLC Has $552,000 Stock Holdings in CareDx, Inc (NASDAQ:CDNA)

Sherbrooke Park Advisers LLC grew its position in CareDx, Inc (NASDAQ:CDNA - Free Report) by 226.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,800 shares of the company's stock after buying an additional 17,885 shares during the quarter. Sherbrooke Park Advisers LLC's holdings in CareDx were worth $552,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Swiss National Bank increased its stake in shares of CareDx by 1.9% in the 4th quarter. Swiss National Bank now owns 98,600 shares of the company's stock valued at $2,111,000 after purchasing an additional 1,800 shares during the last quarter. Barclays PLC grew its position in CareDx by 123.8% in the third quarter. Barclays PLC now owns 98,505 shares of the company's stock valued at $3,075,000 after acquiring an additional 54,482 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in CareDx by 59.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 327,343 shares of the company's stock worth $7,008,000 after acquiring an additional 122,356 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in CareDx during the fourth quarter worth about $208,000. Finally, Principal Financial Group Inc. lifted its holdings in shares of CareDx by 6.5% in the fourth quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock worth $406,000 after acquiring an additional 1,151 shares during the last quarter.

Analyst Upgrades and Downgrades

CDNA has been the subject of a number of research reports. The Goldman Sachs Group dropped their target price on shares of CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a report on Thursday, April 17th. Stephens reissued an "overweight" rating and issued a $40.00 target price on shares of CareDx in a report on Monday, May 5th. HC Wainwright reissued a "neutral" rating and issued a $25.00 target price on shares of CareDx in a report on Monday, May 5th. Finally, Wall Street Zen cut shares of CareDx from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $30.33.

Insider Buying and Selling at CareDx

In related news, Director Peter Maag sold 13,281 shares of the company's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $17.23, for a total transaction of $228,831.63. Following the sale, the director now owns 316,743 shares in the company, valued at $5,457,481.89. This represents a 4.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christine Cournoyer sold 29,136 shares of CareDx stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $15.96, for a total value of $465,010.56. Following the completion of the sale, the director now owns 37,045 shares of the company's stock, valued at approximately $591,238.20. The trade was a 44.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 59,382 shares of company stock valued at $934,509. 4.90% of the stock is currently owned by company insiders.

CareDx Trading Up 0.4%

CDNA traded up $0.06 on Thursday, reaching $17.11. The stock had a trading volume of 571,273 shares, compared to its average volume of 891,771. The firm has a 50-day moving average of $17.56 and a 200-day moving average of $20.83. The company has a market capitalization of $952.70 million, a price-to-earnings ratio of -6.34 and a beta of 2.27. CareDx, Inc has a fifty-two week low of $12.90 and a fifty-two week high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business had revenue of $84.69 million during the quarter, compared to the consensus estimate of $84.56 million. During the same period in the prior year, the business posted ($0.03) earnings per share. CareDx's quarterly revenue was up 17.6% on a year-over-year basis. Sell-side analysts anticipate that CareDx, Inc will post -0.9 EPS for the current fiscal year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.